Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,020 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Wang Z, Zhu S, Zhao J, Nie L, Chen X, Zhang M, Chen N, Sun G, Chen J, Ni Y, Dai J, Liu Z, Tao R, Zhang X, Zhu X, Zhang H, Liang J, Wang Z, He B, Shen P, Zeng H. Wang Z, et al. Among authors: he b. Prostate. 2021 Nov;81(15):1191-1201. doi: 10.1002/pros.24215. Epub 2021 Aug 26. Prostate. 2021. PMID: 34435696 Free PMC article.
Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis.
Chen J, Zhang Y, Zhang X, Zhao J, Ni Y, Zhu S, He B, Dai J, Wang Z, Wang Z, Liang J, Zhu X, Shen P, Zeng H, Sun G. Chen J, et al. Among authors: he b. Front Pharmacol. 2022 Jan 18;12:789319. doi: 10.3389/fphar.2021.789319. eCollection 2021. Front Pharmacol. 2022. PMID: 35115934 Free PMC article. Review.
Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S, Zhao J, Nie L, Yin W, Zhang Y, Zhao F, Ni Y, Zhang X, Wang Z, Dai J, Liu Z, Chen J, Zeng Y, Wang Z, Sun G, Liang J, Zhao X, Zhu X, Tao R, Yang J, He B, Chen N, Shen P, Zeng H. Zhu S, et al. Among authors: he b. BMC Med. 2022 Jul 22;20(1):237. doi: 10.1186/s12916-022-02430-0. BMC Med. 2022. PMID: 35864546 Free PMC article.
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z, Liu H, Zhao J, Chen J, Zhu S, Dai J, Ni Y, Xu N, Zhao F, He B, Zhang X, Liang J, Sun G, Liu Z, Shen P, Zeng H. Wang Z, et al. Among authors: he b. Ann Transl Med. 2023 Mar 15;11(5):201. doi: 10.21037/atm-22-4318. Epub 2023 Mar 9. Ann Transl Med. 2023. Retraction in: Ann Transl Med. 2023 Jun 30;11(9):332. doi: 10.21037/atm-2023-7 PMID: 37007568 Free PMC article. Retracted.
Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z, Liu H, Zhao J, Chen J, Zhu S, Dai J, Ni Y, Xu N, Zhao F, He B, Zhang X, Liang J, Sun G, Liu Z, Shen P, Zeng H. Wang Z, et al. Among authors: he b. Ann Transl Med. 2023 Jun 30;11(9):332. doi: 10.21037/atm-2023-7. Epub 2023 Apr 12. Ann Transl Med. 2023. PMID: 37404997 Free PMC article.
8,020 results